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The acquisition of a fully malignant phenotype is limited by several barriers, including cellular senescence and
the requirement to undergo an epithelial-mesenchymal transition (EMT). Deregulation of these processes is
believed to occur by largely independent events. In this issue of Cancer Cell, Ansieau et al. (2008) challenge
this view.Tissues often contain several small and
inconspicuous neoplastic lesions, which
rarely progress to full malignancy. It is be-
lieved that multiple factors underlie this
phenomenon. These include apoptosis,
the necessity to acquire invasive compe-
tence, and the activation of a cellular
senescence program. The last of these
is receiving increased attention, moving
from being a phenomenon seen exclu-
sively in cultured cells to one constituting
a critical tumor suppression function in
vivo. It can be triggered by telomere
malfunction or unscheduled activation of
oncogenic signaling (Prieur and Peeper,
2008). Cellular (oncogene-induced) se-
nescence is characterized by a largely ir-
reversible cell-cycle arrest, often a typical
flattened cell morphology, and induction
of a tumor suppressor network.
Another factor proposed to limit pro-
gression of epithelial tumors is the re-
quirement to undergo epithelial-mesen-
chymal transition (EMT). While important
for embryonic development, EMT is often
adopted by cancer cells, endowing them
with a migratory and/or invasive pheno-
type. It is characterized by decreased
cell adhesion, which is usually accompa-
nied by the downregulation of E-cadherin.
This important epithelial adhesion protein
is regulated by several transcription fac-
tors, including Twist, Snail, and Zeb1.
Although these tumor-restricting pro-
cesses are generally seen as largely inde-
pendent traits, Ansieau et al. (2008) report
that, in fact, they may not be distinctly
autonomous as previously thought. The
authors asked whether Twist1 (overex-
pression of which is linked to breast can-
cer infiltration; Yang et al. [2004]) and
its close cousin Twist2 are activated in
cancer. To address this, they analyzed
MMTV-ErbB2-driven murine mammary
tumors, where TWIST2 levels were in-
creased in the majority of these lesions.
When extending this study to human
breast carcinomas, the authors observed
instead that TWIST1 was upregulated in
half of the cases.
The notion that Twist1 may play a rela-
tively more important role in human breast
cancer was supported when Twist pro-
teins were depleted from T47D human
breast cancer cells harboring multiple
copies of ERBB2. The authors observed
that only TWIST1 knockdown resulted in
a moderate increase in senescence-asso-
ciated b-galactosidase activity (SA-b-gal,
a commonly used marker of senescence).
This was accompanied by a modest in-
crease in the number of cells that actually
underwent cell-cycle arrest, which may be
explained by assuming that the genetic
wiring implementing senescence-associ-
ated proliferative arrest in these cancer
cells is disrupted. In human RPMI 7951
melanoma cells harboring a mutant
BRAFE600 oncoprotein, codepletion of
the two Twist proteins resulted in a similar
response. An interesting question promp-
ted by these observations is whether in the
same setting, Twist is required for the in-
vasive and metastatic capacities of these
cells. Previous work has shown this to be
the case within the context of murine
breast tumor cells (Yang et al., 2004).
A connection between Twist, senes-
cence, and the cell-cycle machinery was
initially suggested almost a decade ago
(Maestro et al., 1999). Twist1 and Twist2
(also called Dermo1) were identified in
a screen for genes antagonizing Myc-in-
duced apoptosis. While Twist1 reversedCancer Cell 14, July 2008 ª2008 Elsevier Inc. 5
Cancer Cell
Previewsthe induction of cell-cycle ar-
rest by p53, a key regulator of
cellular senescence and pro-
liferation, Twist1 and Twist2
were demonstrated to en-
hance oncogenic transforma-
tion of cells expressing E1A
and H-RasV12. Extending these
findings, Ansieau et al. (2008)
show here that both Twist pro-
teins cooperate with H-RasV12
to produce tumors in immuno-
deficient nude mice. Whereas
in Myc-driven apoptosis,
Twist1 primarily suppresses
ARF, Ansieau et al. demon-
strate that in a senescence set-
ting, Twist proteins suppress
p21Cip1 in a p53-independent
manner and p16Ink4a, both at
the promoter level.
The exciting premise that
activation of EMT might be
linked to suppression of
cellular senescence has been
proposed in the context of
another EMT-regulating tran-
scription factor, Zeb1 (Liu
et al., 2008). It was shown
that mutation of Zeb1 in mice causes
a mesenchymal-epithelial transition (MET),
characterized by increased expression of
epithelial proteins such as E-cadherin
and decreased expression of mesenchy-
mal proteins. In addition, Zeb1-deficient
murine embryonic fibroblasts accumu-
lated the cell-cycle-inhibitory protein
p21Cip1 and underwent premature senes-
cence in culture. Ansieau et al. (2008)
show that Twist, too, inhibits the accumu-
lation of p21Cip1, raising the possibility that
this cyclin-dependent kinase inhibitor acts
as a point of signal convergence.
The findings currently reported show
that a link between EMT and senescence
is not specific for Zeb1 but is seen also for
Twist. Exploiting the finding that ectopic
expression of ErbB2 induces cellular
senescence (Trost et al., 2005), Ansieau
et al. (2008) show that coexpression with
either Twist protein suppresses the in-
crease of SA-b-gal activity and the senes-
cence-associated flat cell morphology.
This observation is in keeping with the
previous finding that Twist suppresses
senescence of immortalized human pros-
tate epithelial cell lines (Kwok et al., 2007).
Ansieau et al. (2008) find that the effect
of Twist (in the presence of oncogenic
signals) on cellular senescence is accom-
panied, in the same experimental cell sys-
tem, by EMT. This was illustrated by the
cooperative suppression of epithelial pro-
teins including E-cadherin and claudin,
upregulation of the mesenchymal protein
vimentin, and concomitant morphological
transformation to a fibroblast-like pheno-
type. Therefore, the full manifestation of
both senescence bypass and activation
of EMT seems to require the collaboration
of Twist with oncogenic signals like ErbB2
or Ras. The fact that simultaneous effects
on EMT and senescence have now been
observed for at least three transcription
factors, Twist1, Twist2, and Zeb1, sug-
gests the emergence of a more universal
biological concept, in which key EMT-
regulating transcription factors simulta-
neously regulate invasion, motility, and
senescence (Figure 1).
The findings by Ansieau et al. (2008)
prompt several interesting questions,
such as whether the coordinated deregu-
lation of EMT and senescence reflects
only a ‘‘collateral effect,’’ as the authors
propose. Or are there instead mechanistic
links tying together these two processes?
For example, could an EMT-like process
contribute to senescence bypass? Senes-
cent cells can adopt a ‘‘flat cell
phenotype,’’ in which they
grow to an abnormally large
size, which is often lost when
they bypass senescence,
raising the possibility that se-
nescence is tightly coupled
to cellular morphology. And
conversely, can cells with an
intact senescence program
undergo a full EMT? Indeed,
is it only coincidental that
Twist suppresses the INK4a/
ARF locus (encoding p16Ink4a
and ARF) and CDKN1A (en-
coding p21Cip1), genes that
are so central in senescence
signaling?
Like Twist and Zeb1, the
EMT-regulating transcription
factor SIP1 (which also com-
municates with the cell-cycle
machinery; Mejlvang et al.
[2007]) has E-cadherin as
a transcriptional target; it will
therefore be interesting to
determine whether E-cadherin
has a direct role in cellular
senescence. Furthermore, as
Twist has been implicated in regulating
proinflammatory cytokine gene expression
(Sosic et al., 2003) and as it has recently
been shown that interleukins play a crucial
role in oncogene-induced senescence
(Kuilman et al., 2008; Acosta et al., 2008),
further investigations into the role of cyto-
kines in Twist-dependent cellular senes-
cence are warranted.
So it seems that, by deregulating both
cellular senescence and EMT, proteins
like Twist and Zeb1 can deliver a doubly
damaging effect contributing to tumor
progression. Based on their findings,
Ansieau et al. (2008) challenge the con-
cept that metastasis corresponds to the
final step of the tumorigenic cascade. In-
stead, they propose that the dissemina-
tion of primary tumor cells residing at the
invasive edge may commence early in re-
sponse to environmental cues, coupling
metastatic spread to the bypass of senes-
cence. A link between EMT and senes-
cence is sufficiently fascinating to justify
tackling these questions.
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The etiology of gastrointestinal tumors implicates a role for chronic inflammation in response to pathogenic
microflora as a promoting force for full neoplastic progression. Recently, Oguma and coworkers (2008) dem-
onstrated that TNFa, derived from recruited macrophages, potentiates Wnt/b-catenin signaling and gastric
carcinogenesis by activating Akt signaling and GSK3b phosphorylation independent of the NF-kB pathway in
initiated epithelial cells. These observations provide a missing link in the mechanism whereby chronic inflam-
mation, in response to Helicobacter, regulates the ‘‘penetrance’’ of initiating oncogenic mutations in the
gastrointestinal tract leading to gastrointestinal tumorigenesis.
Epidemiologic studies have long sup-
ported a link between chronic inflamma-
tion and development of solid tumors
(Coussens and Werb, 2002; Thun et al.,
2004). More recently, through utilization
of immunocompetent mouse models of
multistage carcinogenesis, the molecular
mechanisms whereby chronic engage-
ment of the immune system (inflamma-
tion) potentiates development of epithelial
cancers have begun to be elucidated
(Balkwill et al., 2005; de Visser et al.,
2006; Karin et al., 2006). Missing, how-
ever, has been insight into which soluble
mediators derived from chronically acti-
vated immune cells are significant for
regulating the penetrance of neoplastic
cells harboring initiating mutations. For
example, in the gastrointestinal tract,
malignancy is frequently preceded by
chronic inflammation sometimes associ-
ated with Helicobacter pylori infection
(Blaser, 2000) or in individuals harboring
activating mutations in the APC or
CTNNB1 genes or enhanced activation
of Wnt/b-catenin signaling (Clements
et al., 2002).
APC is a multifunctional cytoplasmic
protein whose gene is frequently mutated
in several types of gastrointestinal can-
cers. APC regulates both genomic insta-
bility and hyperactivation of the Wnt/
b-catenin signaling pathway, and nuclear
b-catenin accumulation is found in colon
carcinoma cells at invasive fronts (Fodde
and Brabletz, 2007). Recent experimental
studies have revealed that malignant con-
version of initiatedAPCmutant cells is po-
tentiated by chronic activation of the Wnt/
b-catenin signaling pathway (Fodde and
Brabletz, 2007); however, links between
these molecular mediators and chronic
inflammation have not been previously
identified.
Oguma and coworkers (2008) investi-
gated this link and found that both
enhanced Wnt expression and infection
by gastric microflora induce submucosal
infiltration by macrophages secreting high
levels of tumor necrosis factor-alpha
(TNFa). Binding of TNFa to TNF receptors
on gastric epithelial cells enhances Akt
phosphorylation that in turn induces gly-
cogen synthase kinase 3b (GSK3b) phos-
phorylation, resulting in stabilization and
nuclear accumulation of b-catenin that
potentiates gastric carcinogenesis (Fig-
ure 1). To reveal this pathway, the authors
utilized a mouse model of gastric tumori-
genesis in which Wnt1 is expressed in
gastrointestinal mucosal epithelia, K19-
Wnt1 transgenic mice, which develop
sporadic dysplastic lesions in the glandu-
lar stomach, mimicking hyperactivation
of Wnt/b-catenin signaling commonly ob-
served in patients with gastric carcinoma
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